Fig. 1: Trial profile. | Nature Communications

Fig. 1: Trial profile.

From: Immunogenicity and safety of a recombinant gE-Fc fusion protein subunit vaccine for herpes zoster in adults ≥50 years of age: a randomised, active-controlled, non-inferiority trial

Fig. 1: Trial profile.The alternative text for this image may have been generated using AI.

The immunogenicity PPS analysis set included all participants who received two doses within the preset time window, had no major protocol violations, and had pre- and post-vaccination immunogenicity data available. 6 participants were excluded from immunogenicity PPS analysis set because of the second vaccination time beyond the time window, with 5 in LZ901 group and 1 in HZ/su group, see supplementary table 9. PPS, per-protocol set.

Back to article page